Background. The fulminant form of hepatitis B-related acute liver failure (FHB-ALF) is a rare but highly fatal outcome of acute hepatitis B virus (HBV) infection. Its related host factors have not been studied to our knowledge.
Hepatitis B virus (HBV) can cause self-limiting acute infection or establish chronic infection in liver by blunting host immunity [1] , but the underlying mechanisms remain imperfectly understood. Candidate gene or genome-wide association studies using large samples of patients with chronic HBV infection had only been able to identify known polymorphisms statistically associated with chronicity or carcinoma progression [2, 3] . Little information is available on the role of host genetic variations, especially those affecting antiviral defense, in determining the outcome of acute infections at the early stages of exposure.
In addition to the common self-limiting and chronic infection, rare but extreme outcomes of acute infection offer an alternative and potentially powerful opportunity for probing genes and pathways involved in determining infection outcome. The fulminant form of HBV-related acute liver failure (FHB-ALF) is an extremely rare but fatal outcome of acute HBV infection, defined by the sudden onset and rapid progression of hepatic encephalopathy within 2 weeks after exposure in an otherwise healthy individual [4] . Although the outcome of HBV infection is considered to be largely determined by the kinetics, breadth, and effector functions of HBV-specific adaptive T-cell responses [5] , in FHB-ALF, cytotoxic T-lymphocyte (CTL) responses seem to play an important part [6] .
The actual incidence of FHB-ALF is generally accepted to be low (~1% according to some [7, 8] ) and 1 study has estimated that fatal outcome occurs in about 0.1% of acute HBV infections [9] . Such a low incidence, even in highly endemic regions, suggests that the contributing host genetic traits are probably rare. We collected 10 qualified cases and performed whole-exome sequencing to screen for rare case-specific variants and related pathways. Identified variations were verified by Sanger sequencing, validated against nonfulminant HBV infection controls, and functionally characterized. The possible contribution of viral mutations was also tested.
patients had normal liver function before illness onset, with subsequent development of grade 3-4 hepatic encephalopathy and prolonged prothrombin time within 2 weeks [10] . Acute HBV infection was diagnosed based on serum anti-hepatitis B core (HBc) immunoglobulin M positivity, hepatitis B surface antigen (HBsAg) positivity and absence of preexisting HBV infection [4] .
Controls included patients with nonfulminant acute symptomatic hepatitis B presenting with jaundice or elevated serum alanine aminotransferase (ALT) levels along with immunoglobulin M anti-HBc/HBsAg positivity and compatible clinical history [4] . Chronic hepatitis B (CHB) was diagnosed based on HBsAg seropositivity and persistent or recurrent serum ALT elevations for >6 months; acute-on-chronic liver failure was diagnosed according to the consensus recommendations of the Asian Pacific Association for the Study of the Liver [11] ; patients with resolved asymptomatic self-limiting HBV infection had no history of clinical hepatitis and were positive for antibodies to HBsAg, HBc antigen (HBcAg), and/or hepatitis B e antigen (HBeAg) [12] but negative for HBsAg and HBV DNA. Other potential causes of hepatitis were ruled out, including hepatitis A/C/delta (8)/E virus infection, Epstein-Barr virus infection, cytomegalovirus infection, herpes simplex virus infection, alcohol, Wilson disease, autoimmune hepatitis, acute ischemic injury, malignant infiltration, and drugs. Informed consents were obtained, and the study was approved by the Bioethics Committee of Ruijin Hospital in accordance with the Helsinki Declaration.
Whole-Exome Sequencing
Blood was collected from patients at admission or initial hospital visit. Details on whole-exome sequencing can be found in the Supplementary File.
Case-Specific Variants Calling and Filter Workflow
PICARD software, version 1.119 (Broad Institute), was used to remove polymerase chain reaction (PCR) duplications. Read pairs were realigned around potential indel (insertion and deletion) regions by GATK [13] IndelRealigner software, version 3.6 (Broad Institute), following the recommended pipeline. Base-quality recalibration was carried out using GATK BaseRecalibrator software (Broad Institute) to generate analysis-ready reads.
After that, 3 software programs, including GATK HaplotypeCaller (Broad Institute), Varscan [14] version 2.4.1 (Genome Institute at Washington University), and LoFreq (Genome Institute of Singapore) [15] version 2.1.2, were applied to identify single-nucleotide variations (SNVs) and indels. SNVs and indels detected were subsequently filtered by GATK variant filtration (Broad Institute) and a custom pipeline to exclude (8) mutations with low consensus confidence score, (8) mutations with low sequencing depth, (8) mutations reported in dbSNP database (build 144) as common single-nucleotide polymorphisms with minor allele frequency >0.01, and (8) mutations previously identified in patients with CHB [16] . Filtered mutations were annotated using annotate variation (ANNOVAR) [17] (http://www.openbioinformatics.org/ annovar/), and variations in genes involved in immunity were selected using gene ontology (http://wiki.geneontology.org/ index.php/Immunologically_Important_Genes).
Functional Prediction and Pathway Enrichment Analysis of the Variants
Functional impacts of the variants were predicted by both SIFT (Sorting Intolerant From Tolerant) and Polyphen2 (Polymorphism Phenotyping v2) algorithms. Pathway enrichment analysis was performed using the Functional Annotation Clustering tool in DAVID Bioinformatics Resources, version 6.7 [18] .
Verification and Validation of Identified Mutations
The variations selected by the bioinformatics pipeline was confirmed in case patients using PCR followed by Sanger sequencing. Heterozygous status information was also obtained in this process. The incidence of the confirmed case variations in 312 nonfulminant control patients was checked using Sanger sequencing.
Structural Modeling of Toll-like Receptor 2 Gene Mutation
Multiple sequence alignment of Toll-like receptor (TLR) 2 gene (TLR2) orthologue sequences obtained from the HomoloGene database (http://www.ncbi.nlm.nih.gov/homologene) was performed using Clustal software version 2.1 (Conway Institute UCD Dublin) [19] . To predict the structural effects of TLR2 mutation, sequences of mutant TLR2-Toll/interleukin-1 receptor (TIR) domain were submitted to the I-TASSER server (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) [20] . The predicted 3-dimensional structure model was compared with the published crystal structure of the human TLR2-TIR domain (Protein Data Bank [PDB] identifier, 1FYW) [21] using Chimera software (version 1.5.3; University of California, San Francisco) [22] .
Functional Characterization of the TLR2 Mutation
TLR2 function was investigated in HEK293 cells cultured in Dulbecco's minimum essential medium supplemented with 10% fetal calf serum, penicillin, and streptomycin (Invitrogen Gibco BRL). Cells were transfected with plasmids expressing FLAGtagged wild-type or mutant TLR2 or a 1:1 mixture of both in addition to an NF-κB-inducible firefly luciferase reporter plasmid pGL4.32 (Promega). Renilla luciferase plasmid hRL-tk (Promega) was used as the transfection control. Transfected cells were stimulated with synthetic TLR1/TLR2 agonist Pam3CSK4 (Invivogen). TLR1/TLR2-mediated NF-κB activation was analyzed using the Dual-Luciferase reporter system (Promega).
Plasmid pWT (wide type) contains a terminally redundant 1.2× copy of genotype C HBV genome [23] . Mutations T1753C, A1762T/G1764A, and G1896A were introduced into pWT using site-directed mutagenesis to create pMT (mutant type). The empty vector, produced by removing HBV genome from pWT, was used as a control.
Mice
Age-and weight-matched C57BL/6 wild-type and TLR2 knockout (KO) (B6.129-Tlr2 tmIkir /NJU) mice were obtained from the Model Animal Research Center of Nanjing University, China. TLR2 +/− mice were obtained by crossing homozygous TLR2 KO mice with C57BL/6. Genotypes were confirmed, and mice were maintained under specific pathogen-free conditions in the Animal Resources Laboratory at Ruijin Hospital, with animal care and experimental protocols approved.
Hydrodynamic Transfection
Male mice 8-10 weeks old were injected with 20 μg of plasmid DNA through the tail vein in a volume of Ringer's lactate solution equivalent to 8% body weight. The total volume was delivered within 3-8 seconds.
Measurement of ALT, HBsAg, HBeAg, and HBV DNA
In hydrodynamic injection experiments, serum was collected by retro-orbital bleeding at baseline and at days 3, 7, 14, 17, and 21 and weeks 4 and 5 after injection. ALT was measured using an automated chemistry analyzer (Beckman Coulter). HBsAg and HBeAg were measured using the Abbott Architect immunoassay system (Abbott Laboratories). HBV DNA levels were measured by real-time PCR using the Cobas Amplicor HBV Monitor Test (Roche Diagnostics), with a lower limit of 60 IU/ mL.
Flow Cytometry Analysis
Monocytes in liver and spleen were prepared and stained [24] with fluorescein isothiocyanate-labeled anti-mouse CD3e, V450-labeled anti-mouse CD4, and peridinin-chlorophyll protein-labeled anti-mouse CD8a from BD Biosciences and allophycocyanin-labeled anti-mouse CD25 and R-phycoerythrin-labeled anti-mouse Foxp3 from eBioscience. At least 20 000 events gated among the population of interest were acquired on a FACS Canto II cytometer using Diva software, version 6.2 (BD Biosciences) and analyzed with FlowJo software, version 7.6.1 (Tree Star).
Histological and Immunohistochemical Analyses
Liver sections were stained with hematoxylin [25] , and HBcAg or HBsAg was detected by means of immunohistochemical staining using polyclonal rabbit antibodies [26] . One histopathologist (H. Z.) single blindly graded the severity of liver necroinflammation, using the Scheuer scoring system [27] .
HBV Sequencing and Genotyping
HBV DNA was extracted from serum samples from patients with FHB-ALF using the QIAamp blood mini kit (Qiagen). Whole HBV genomes were then amplified using nested PCR and directly sequenced. HBV genomic sequences were aligned with reference strains (AB073826 for genotype B and AF286594 for genotype C) for genotyping and mutation analysis.
Statistics
Data are expressed as means with standard errors of the mean. Comparisons of data among groups were made using 1-way analysis of variance followed by the Fisher's Least Significant Difference multiple-comparison test. Statistical tests were 2 sided. The statistical differences were analyzed using GraphPad Prism software, version 6.00. Differences were considered significant at P < .05.
RESULTS

Enrichment of Rare Mutations in TLR2 Pathway Among Patients With
FHB-ALF
Because of the extremely low incidence and strict enrollment criteria adopted [10] , we were only able to establish a case group consisting of 10 unrelated patients (Table 1 and  Supplementary Table 1 ). Genomic DNA samples from patients with HBV infection of nonfulminant outcomes, including 124 with asymptomatic self-limiting HBV infections, 65 with acute symptomatic hepatitis B, 93 with CHB, and 30 with acute-on-chronic liver failure were collected in parallel as outcome controls.
Variations identified by exome sequencing fall within coding regions. From all high-confidence exome variations, we selected rare and nonsynonymous variations. By applying the well-established David pathway enrichment tool on the filtered rare and case-specific protein-altering variations, the TLR pathway was shown to be significantly enriched in the FHB-ALF group, with 9 of 10 patients harboring related variants ( Figure  1 ). These genes included TLR2, TIRAP, IRF7, IFNAR2, TRAF6, TLR1, SPP1, MAPK12, IRF5, IRAK1, IKBKE, and IFNAR1, most of them directly functioning within the TLR2 pathway (Supplementary Table 2 ). All variations were missense mutations. Their potential functional consequences were evaluated by both SIFT and Polyphen2 algorithms. Most notably, an identical TLR2 SNV (Figure 2A ) causing F679I mutation in TLR2 protein was found in 2 patients (F1 and F10), and is significantly enriched in case group compared with both the nonfulminant outcome group (0% incidence; P < .001 [χ 2 test, Yates correction for continuity]), and general population (0% incidence; 1KGenomes project data, 2011 release [28] ; P < .001).
Perturbed Structure of the TLR2 Mutant F679I
F679I mutation is located within the cytoplasmic TIR domain of TLR2 [29] that is highly conserved among species ( Figure 2B ). X-ray crystallography showed that residue 679 is located in the surface-exposed BB loop (BB5) connecting βB and αB. I-TASSER [30] predicted that ion-pair interaction between Arg677 in BB3 and Glu664 near the end of helix αA [21] is perturbed in the TLR2-F679I mutant ( Figure 2C ).
Loss of Function Caused by TLR2 F679I Mutation
Functional consequences of F679I mutation were then experimentally tested in vitro using HEK293 cells, which lack endogenous TLR2 expression. After transfection with wild-type or F679I mutant TLR2 expression plasmids ( Figure 2E) a NF-κB-responsive luciferase reporter, cells were stimulated with the TLR1/TLR2 agonist Pam3CSK4, and relative luciferase activities in cell lysates were measured as indicators of TLR1/ TLR2-mediated NF-κB activation. HEK293 transfected with wild-type TLR2 displayed significant NF-κB pathway activation on stimulation, whereas F679I-transfected cells displayed almost zero activation, indicating that the single amino acid substitution results in loss of function. When wild-type and F679I mutant were cotransfected at a 1:1 ratio, NF-κB pathway activation decreased by about 50% ( Figure 2D ).
TLR2 Knock Out and Sensitization to Liver Damage After HBV Exposure in Mice
Hydrodynamic Transfection of Mice With HBV Replicon Plasmid
Because TLR2 F679I mutation results in loss of function, the possible link between this mutation and liver failure was investigated using TLR2 KO mice, and tail-vein hydrodynamic injection of 1.2× HBV genome plasmid was used to simulate acute HBV exposure. Heterozygous TLR2 KO mice were previously shown to display reduced cytokine production in response to certain TLR2 agonists [31, 32] . Wild-type genotype C HBV plasmid pWT and its derivative pMT carrying the T1753C/A1762T/G1764A/G1896A mutations found in patient F10 were used, with vector as control. In all mice injected with pWT or pMT, but not with vector, regardless of TLR2 genetic status, serum HBsAg and HBV DNA could be detected at day 3 after injection and decreased thereafter, reaching near or below the detection limit by day 17 after injection. No statistically significant difference in serum HBsAg or HBV DNA levels was observed between the groups. Similar trends were observed for serum HBeAg, but only in pWT-injected mice, because the G1896A mutation in pMT prematurely terminates the HBeAg open reading frame (Figure 3) . Immunohistochemistry also confirmed HBsAg and HBcAg expression in hepatocytes from mice injected with pWT or pMT (Supplementary Figure 1) .
Elevated Serum ALT in TLR2 KO Mice Hydrodynamically Transfected With HBV
No marked ALT anomalies were observed in wild-type mice injected with either pWT or pMT, but serum ALT increased to abnormal levels after injection in a majority of heterozygous and homozygous TLR2 KO mice transfected with either pWT or pMT, peaking between weeks 1 and 3 after injection. Statistical analyses using peak ALT values showed that TLR2 +/− and TLR2 −/− mice displayed severe ALT elevations after pWT or pMT transfection, and in TLR2 +/− mice, significantly higher ALT levels were observed after pMT injection than after pWT injection (Figure 3 ).
Necroinflammation in TLR2 KO Mice After HBV Exposure
As there were variations in ALT peak times even among different mice in the same group, mice were killed at week 5 after injection, when ALT peaks had passed, as confirmed by serum ALT analyses (Figure 3) , and livers were removed for immunohistochemical and histopathological analyses. Although HBV antigen and DNA were cleared from serum by week 3 after injection in all mice injected with pWT or pMT, intrahepatic necroinflammation was observed only in pWT-injected TLR2 +/− and TLR2 −/− mice, as well as in pMT-injected TLR2 +/− mice. Single-blind Scheuer scoring ranked necroinflammation in pMT-injected TLR2 +/− significantly (P < .05) higher than in pWT-injected TLR2 +/− or TLR2 −/− mice ( Figure 4 ).
Decreased Regulatory T Cells After HBV Exposure in TLR2 +/− and
Liver damage in hepatitis B is generally believed to be the result of cell-mediated immune attacks [33] . To probe the possible underlying mechanisms contributing to the different profiles of ALT fluctuations and liver histopathological changes after HBV exposure, intrahepatic mononuclear cells and splenocytes from TLR2 +/+ , TLR2 +/− and TLR2 −/− mice were assessed before and after injection ( Figure 5 ). Fluorescence-activated cell sorting analysis of major populations of T lymphocytes (CD4 + , CD8 + and CD25 + FoxP3 + ) in wild-type and TLR2 KO mice revealed no significant difference at baseline, whereas decreased levels of CD25 + FoxP3 + regulatory T (Treg) cells were found in heterozygous and homozygous TLR2 KO mice compared with wild-type mice at 2 weeks after injection with HBV plasmids. The differences were significant (P < .05) in the liver. 
HBV Mutations in Patients With FHB-ALF and TLR2 F679I Mutation
HBV genome was successfully amplified using nested PCR from patient F10. This patient was infected with subgenotype C2 with multiple previously reported mutations [34] , including basal core promoter double mutation A1762T/G1764A, precore stop codon mutation G1896A, and another basal core promoter mutation T1753C. No novel HBV mutation was found.
DISCUSSION
Assuming that host genetic factors play a role in determining outcome of acute HBV infection, characterizing genetic variations exclusively or predominantly found in persons with FHB-ALF is the natural path to follow. Unfortunately, owing to the low incidence of cases and the strict diagnosis criteria employed, the number of cases collected in this work is too small to apply the common strategy of variation identification in the discovery group followed by replication using a separate replication group. As an alternative, we subjected case-specific, potentially deleterious protein-altering variations to pathway enrichment analysis, in the hope that insight into fulminancy pathogenesis could be gained at pathway level by incorporating information on multiple genes. The enrichment approach applied is widely accepted [18] and attempts to group a set of genes based on pathway annotations and identify a pathway or pathways whose member genes are overrepresented compared to other pathways.
Our results indicate that the incidence of rare and deleterious variations in TLR signaling pathway genes exclusively found in patients with FHB-ALF was highest among all affected pathways. Most of these genes closely cluster within the TLR2 pathway. TLR1 heterodimerizes with TLR2 and signals through the TIR domain. Toll/interleukin-1 receptor domain-containing adapter protein (TIRAP) is responsible for signaling selectively downstream of TLR2 and TLR4 and induces NF-κB activation [35] . Most notably, the same rare and deleterious TLR2 SNV was found in 2 patients with FHB-ALF. It causes a Phe-to-Ile change at the phylogenetically conserved position 679 of TLR2, which is located within the TIR domain. The affected region is highly conserved in all TLR2 orthologues across different species, including insects, and almost all mutations in this region abolished receptor signaling [21] .
Structural simulation showed that TLR2 F679I mutation causes local structural disturbances, and functional analysis in vitro confirmed that the mutation indeed causes loss of function. Both affected patients were heterozygous for F679I. Cotransfection assay and assays using heterozygous TLR2 KO mice [31, 32] indicated that magnitude of TLR2-mediated signaling correlates with wild-type TLR2 allele dosage.
Current knowledge regarding HBV and TLR2 was obtained mostly from chronic infection [36, 37] , and its role in HBV infections seems complicated. On one hand, TLR2 signaling is capable of enhancing the HBV-specific T-cell responses in the liver [38] . On the other, ligands of other major TLRs, but not TLR2, inhibit HBV replication in the liver noncytopathically within 24 hours in an α/β-interferon (IFN)-dependent manner [39] . This does not necessarily mean that HBV evades the surveillance of TLR2. Instead, HBV capsids are recognized by TLR2 [40] , but such recognition apparently leads to the release of proinflammatory cytokines and interleukin 10, rather than type I IFNs [41] . Somewhat in line with these results, patients with nonfulminant acute HBV infections tend to display higher plasma interleukin 10 levels, which have been shown to exert tissue-protective and immunoregulatory effects [42] , but no increase in antiviral type I IFNs [43] . It is therefore not impossible that, at least in some cases, TLR2 signaling contributes toward prevention of overactive anti-HBV responses.
As mentioned earlier, and possibly different from the situation in chronic HBV infections [44] , CTL responses play an important part in acute setting [6, 45] . In vivo, maturation and effector activity of CTL are under strict control and Treg cells have been demonstrated to be essential for negative modulation of antigen-specific CTL response [46, 47] . TLR2 agonist has been shown to cause expansion of Treg cells in mice [48] . Our investigations also revealed decreased Treg cell levels after HBV exposure in heterozygous and homozygous TLR2 KO mice after HBV plasmid injection ( Figure 5 ).
Based on our results, it can be hypothesized that in HBV infection, TLR2 signaling that is activated by HBV components regulates Treg cell functions and thus suppresses host CTL response, allowing HBV to establish extensive infection in the liver. Deficiency in host TLR2 functions could therefore lead to relaxed control of CTL response, which in turn causes massive killing of hepatocytes, giving rise to acute hepatic failure observed in FHB-ALF.
In addition, our results suggested that, at least in TLR2 KO mice, specific HBV mutations also might contribute to modifying inflammatory responses after exposure. Virus mutations have been suspected of affecting infection outcome. Ozasa et al [34] reported that among acutely infected patients, basal core promoter double mutation (A1762T/G1764A) and precore stop codon mutation (G1896A) were found more frequently in patients developing fulminant hepatitis within 8 weeks than in those with self-limited outcome. However, these mutations are also frequently found in patients with CHB [49] . A study by the US Acute Liver Failure Study Group [50] found that precore stop and core promoter dual mutations were detected in 32% of patients with ALF (FHB) and 44% with CHB. Therefore, these mutations might play roles in FHB pathogenesis in only some cases, but not all. This is also reflected in the fact that in the current study, although all 10 cases of FHB-ALF resulted from horizontal infections in adulthood, the patients were not related to each other in any way, and there was no evidence of clustered fulminantlike cases surrounding them. Whether these viral mutations exert additional effects on TLR2 signaling in patients with FHB-ALF, which is already affected by mutations in host genes, is an important question to be addressed in future.
In conclusion, pathway enrichment analysis of rare, case-specific, potentially functionally deleterious variations highlights TLR2 signaling pathway as one of the pathways most likely to be involved in contributing to fulminant outcome, while functional analysis of an inactivating mutation in TLR2 found in 2 of 10 patients with FHB-ALF studied using HBV-injected KO mice strongly supports participation of TLR2 in HBV pathogenesis. Comprehensive characterization of these case-specific mutations and creation of corresponding animal models will facilitate the understanding of the precise molecular mechanisms at the initial stage of HBV infection and accelerate the development of therapeutics for hepatitis B.
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